<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="1" offset="0" totalResults="1"><SearchResults><Trial Id="78401"><Indications><Indication>Allergic rhinitis</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Glucocorticoid receptor agonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anti-inflammatory</Action><Action>Respiratory system agent</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Aerosol formulation inhalant</Technology><Technology>Inhalant formulation</Technology><Technology>Microparticle formulation</Technology><Technology>Nasal formulation local</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>GlaxoSmithKline plc</Company></CompaniesSponsor><DateChangeLast>2017-05-25T00:00:00Z</DateChangeLast><DateEnd>2011-05-31T00:00:00Z</DateEnd><DateStart>2009-12-31T00:00:00Z</DateStart><Identifiers><Identifier>113407</Identifier><Identifier>NCT01376206</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>fluticasone furoate (nasal, allergic rhinitis), GSK alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2000</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this study was to investigate possible problems or questions in safety and efficacy of Allermist nasal spray in Japanese patients with allergic rhinitis under the practical use conditions.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Allergic rhinitis - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Elderly Adults (80 and over)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TitleDisplay>Drug Use Investigation for Allermist</TitleDisplay><PrimaryCompletionDate type="Actual">2010-09-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>17 Months</TrialDuration><NumberOfSites>0</NumberOfSites><ContactNames><Name>GSK Clinical Trials</Name></ContactNames></Trial></SearchResults></trialResultsOutput>